logo
New Mexico's Four Corners Generating Station could see operations continue beyond 2031

New Mexico's Four Corners Generating Station could see operations continue beyond 2031

Yahoo12 hours ago
Aug. 19—New Mexico's Four Corners Generating Station may see coal-based operations past 2031, potentially preserving more than 200 jobs tied to its operations.
The change in direction comes as Arizona Public Service — the majority owner of the Fruitland plant — has shifted its clean energy goals from being "zero carbon" to "carbon neutral" by 2050, company officials said. The utility, whose only New Mexico operation is the Four Corners plant, made the decision based on energy market changes and customer needs, Arizona Public Service spokesperson Jill Hanks wrote to the Journal.
"With Arizona's population and economy continuing to grow at record levels, so does the state's need for reliable electricity," Hanks said. "Moreover, as part of our focus on providing reliable energy at the lowest cost possible, we need to be able to integrate the most reliable and cost-effective resources available to us to meet the growing need for electricity."
Hanks said APS has not made a decision to continue operating Four Corners past 2031, in particular, but that the company now expects its exit from coal to be "no later than 2038," which would still be consistent with the plant's lease. Currently, the plant employs 251 people and around 100 contractors, she said.
Four Corners is the last operating coal-fired power plant in New Mexico. It was accompanied in the past by the now-decommissioned San Juan Generating Station and Escalante Generating Station.
Hanks said power generated at Four Corners serves Arizona Public Service, the Salt River Project and Tucson Electric Power service territories in Arizona, as well as the Public Service Company of New Mexico's territory.
APS officials have previously said they'd cease Four Corners operations by 2031.
"In short, coal is an important part of our balanced energy mix today, and we will not exit it any earlier than is in the best interests of our customers to ensure reliable service at the lowest cost possible," Hanks said.
The Four Corners plant, located in San Juan County, is a major economic driver for the Navajo Nation, contributing over $59 million annually. According to its website, the Navajo Transitional Energy Co. (NTEC) acquired 7% ownership in Units 4 and 5 of the plant in 2018, a first for the enterprise.
The remaining ownership is split among Arizona Public Service with 63%, PNM with 13%, Salt River Project with 10%, and Tucson Electric Power with 7%.
Last October, the NTEC was awarded $6.5 million from the U.S. Department of Energy's Office of Clean Energy Demonstrations for an engineering design study to determine the feasibility of adding carbon capture to Four Corners.
PNM attempted to exit from Four Corners and transfer its stake to the NTEC by 2024, but was denied by the state Public Regulation Commission. A PNM spokesperson said Tuesday the utility plans to exit from the plant by 2031.
"APS remains committed to clean-energy resources that are cost-competitive and help ensure reliable service for our customers," Hanks said. "Clean-energy resources — such as solar paired with battery-energy storage — that provide a 'best-fit, least-cost' solution to serving our customers will continue to be a key part of how we provide reliable service at the lowest cost possible."
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pfizer battles another Paxlovid lawsuit from Enanta
Pfizer battles another Paxlovid lawsuit from Enanta

Yahoo

time21 minutes ago

  • Yahoo

Pfizer battles another Paxlovid lawsuit from Enanta

If you don't succeed at first, try again – in separate regions. That's the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent infringement relating to Covid-19 treatment pill Paxlovid (nirmatrelvir/ritonavir). In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma company infringed on a patent describing protease inhibitors invented by its scientists. Enanta has now followed that up with another filing in Europe, making the same accusation. Since being emergency authorised in 2021, anti-viral Paxlovid has generated Pfizer more than $26bn in global revenue. This includes a staggering $18.9bn in 2022 when Covid-19 cases were still prevalent. Despite waning demand for Covid-19 treatments, the pill still brought in $1.2bn in 2024, buoyed by government orders. However, Enanta – known for co-developing hepatitis C virus treatment glecaprevir/pibrentasvir with AbbVie – believes Pfizer designed Paxlovid via unlawful means. The US biotech stated it is 'seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's Covid-19 antiviral, Paxlovid'. In an emailed statement to Pharmaceutical Technology, a Pfizer spokesperson said: 'We are confident in our intellectual property (IP) surrounding Paxlovid and will respond in due course in court.' The lawsuit, filed in the European Union's (EU) Unified Patent Court (UPC), targets Pfizer's commercial activity in the 18 countries of the EU. The company confirmed the '265 patent in question is the European counterpart of US patent number 11,358,953 (the '953 Patent) that is the centre of the US lawsuit. Although it is technically ongoing, Enanta's US lawsuit hit a major roadblock. In December 2024, a federal judge in Massachusetts sided with Pfizer, granting that the '953 patent is invalid. Enanta confirmed at the time it would appeal the decision, adding it 'believes strongly in the merits of our case'. Pfizer reported strong Q2 2025 results this month, bucking a tepid earnings window that gripped the wider pharma industry. Sales for the Paxlovid grew 71% while the Covid-19 vaccine Comirnaty revenue surged 95%. However, the legal challenge posed by Enanta marks the second issue Pfizer has had to firefight this week. The big pharma company reported a Phase III trial failure for a sickle cell disease candidate purchased as part of a $5.4bn takeover of Global Blood Therapeutics in 2022. "Pfizer battles another Paxlovid lawsuit from Enanta" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Nasdaq slides again as AI jitters rattle tech investors
Nasdaq slides again as AI jitters rattle tech investors

Yahoo

time21 minutes ago

  • Yahoo

Nasdaq slides again as AI jitters rattle tech investors

NEW YORK (Reuters) -Tech stocks are leading declines on Wall Street, with worries about AI spurring debates about its future. The Nasdaq Composite is down around 2.4% over the last two days, the worst two-day fall since April. The semiconductor index was down 1.5%, while the information technology sector was the second biggest decliner in the S&P 500, dropping 1.1% on Wednesday. Market participants attributed the selloff to a range of factors including a technical pullback after driving much of the stock market's recovery in the weeks after April 2nd "Liberation Day." Analysts also cited deepening concerns of government interference with companies, as the Trump administration looked into taking equity stakes in chip companies such as Intel in exchange for grants under the CHIPS Act. COMMENTS: ART HOGAN, MARKET STRATEGIST, B. RILEY WEALTH MANAGEMENT, BOSTON: "Technology in general is up 40% from its April lows, and the group clearly got ahead of itself. Also, if there's anything to the market consensus that we'll see a Fed rate cut, then there will be room for other things to work as well – and there are 493 other stocks in the S&P 500 that are lagging the Mag 7 right now. So I think there's a bit of a rotation." "I don't know how long it will last, but if it does keep going, well, August and September (are) the weak period seasonally in which it could do so. Also, there are some people who are beginning to question the pace at which we need to be chasing AI capital spending. If you put all this together: when technology stocks take a breather, this is what it looks like. Nvidia and other blue chips in the group are seeing relatively steady drawdowns, but things on the speculative edge are clearly seeing more selling pressure. Palantir has gone from trading at 200 times sales to 150 times its sales, for instance." MICHAEL ASHLEY SCHULMAN, CHIEF INVESTMENT OFFICER, RUNNING POINT, EL SEGUNDO, CALIFORNIA: "Tuesday' s U.S. technology stock swoon and its continuation today looks like multiple compression meeting a little margin math, but the timing makes it hard to ignore the new elephant in the server room. Names that had been sprinting on AI dreams pulled back hard, with Nvidia, AMD, and Palantir Technologies among the drags." "DeepSeek's update landed on Tuesday represents a serious cocktail of capability and availability and traders well remember the original harsh tech-market pullback DeepSeek caused when it was first broadly recognized in January of this year." BRIAN JACOBSEN, CHIEF ECONOMIST, ANNEX WEALTH MANAGEMENT, BROOKFIELD, WISCONSIN: "When you go from rally to rout, it shows how vulnerable the names were to even a scent of bad news. It could have been (Sam)Altman's valuation warning and then Meta restructuring its AI division threw fuel on the fire." PHIL BLANCATO, CHIEF EXECUTIVE OFFICER, LADENBURG THALMANN ASSET MANAGEMENT, NEW YORK: "It's much more about profit-taking and temporary rebalancing here. If you get a Federal Reserve cut or a mention of it on Friday, this will reverse pretty quickly, but this is a lot to do with names pushed up to really lofty levels and profit taking across the board." SETH HICKLE, PORTFOLIO MANAGER, MINDSET WEALTH MANAGEMENT, INDIANAPOLIS: "I think we are starting to see a little bit of rotation. It's always healthy to see a little bit of a pullback to that way, the markets can kind of get re-oriented." "To me, tech was overbought. Maybe it was justified, but it could have been kind of a buy on the rumor, sell it on the news type of thing where we had tech runup into earnings. We had really good earnings, and now it's kind of natural for the market just to sell some of that good news." "I wouldn't be surprised if we see a little bit of rotation into some smaller cap or into healthcare names, or consumer staples. And to me, that's kind of a healthy rotation. But honestly, I don't believe it will be a longer-term trend. It'll probably be a shorter-term trend. I think we'll see money flow back into tech in the next couple months." STEVE SOSNICK, CHIEF STRATEGIST, INTERACTIVE BROKERS, CONNECTICUT "The tech-led selloff that we saw yesterday resumed this morning. That said, dip buyers stepped in around 11am EDT and we've now recovered about half our losses. It's somewhat inevitable to expect them to arrive promptly, though it did take a bit longer than usual." "I believe that some of the early declines are related to profit-taking and risk squaring ahead of (Fed Chair Jerome)Powell's speech on Friday. That is merely rotation and relatively benign, though it gets magnified because of megacap tech stocks' heavy weighting in key indices. But some of the ferocity of the early drop was related to the President's calls for Lisa Cook's resignation." "Note that futures broke through their pre-market lows shortly after he posted on Truth Social. Markets were not perturbed that there are inquiries into the propriety of her personal mortgage applications. She gets a presumption of innocence until proven guilty, like any other person. But when the President weighed in even before the process began, then it raised the specter of politicization. That put markets on the wrong foot early, and negative momentum ruled again – at least for a couple of hours." ADAM SARHAN, CHIEF EXECUTIVE, 50 PARK INVESTMENTS, NEW YORK: "To see a little pullback here after a big move up is perfectly normal and healthy. If the selling gets worse then you'll see a rotation out of tech and into undervalued areas of the market like biotech stocks or healthcare stocks or small cap stocks because those areas have not participated this year." Sign in to access your portfolio

TX RX Systems Launches New 'Deepwave' Antenna Line to Fill Industry Gap
TX RX Systems Launches New 'Deepwave' Antenna Line to Fill Industry Gap

Yahoo

time21 minutes ago

  • Yahoo

TX RX Systems Launches New 'Deepwave' Antenna Line to Fill Industry Gap

TX RX Systems Deepwave Antennas BUFFALO, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- TX RX Systems, a leader in RF conditioning and communications technology for nearly five decades, has announced the launch of its new Deepwave antenna series. This is a comprehensive product line designed to serve as the next-generation solution for organizations seeking high-performance VHF and UHF omnidirectional antennas similar to those found in now-unavailable legacy lines. Engineered and manufactured on-site in the United States, Deepwave antennas deliver industry-proven performance at a significantly lower cost than comparable offerings currently available in the market. Designed for both mission-critical and commercial applications, the line is suitable for integrators, public safety agencies, utilities, transportation providers, manufacturing facilities, government entities, and any organization requiring durable, broadband RF coverage. The new Deepwave series features wideband coverage across VHF and UHF ranges, allowing flexible deployment across multiple systems and jurisdictions. Models are available with nominal gains ranging from 3 dBd to 9 dBd, providing consistent coverage and minimal distortion throughout the entire operating band. Low VSWR, typically 1.5:1 or less across the specified frequency range, ensures efficient power transfer and reduced reflected power. Each antenna is designed to handle high transmit power levels, making them ideal for both high-site and dense urban installations. Durability is a core design priority for the Deepwave line. Heavy-duty fiberglass radomes and stainless steel hardware protect against extreme weather conditions including high winds, ice loading, and salt fog exposure. All models are engineered to meet or exceed ANSI/TIA-222 standards for structural integrity, ensuring reliable operation even in the harshest environments. 'With the discontinuation of several long-standing antenna product lines in the market, organizations are actively seeking drop-in replacements that match or exceed the performance of their existing infrastructure,' said Jay Slomba, Director of Business Operations at TX RX Systems. 'Deepwave antennas are engineered to deliver uncompromising quality at a price point well below what customers are used to paying.' The Deepwave series is available now through the TX RX Systems website. Additional models will be released in the coming months to expand the range and cover even more application requirements. For more information or to request a quote, visit or contact a TX RX Systems Customer & Technical Support Specialist at sales@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store